EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4 /6 Inhibitors Plus Endocrine Therapy in Patients With HR ‐Positive, HER2 ‐Negative Breast Cancer: A Retrospective Single‐Centre Cohort Analysis

Xiaopei Dong iD, Fan Li iD, Yang Yuan, Hua Song, Yingzhe Wang, Yi Hao, Yinping Dong, Tao Wang, Li Bian, Shaohua Zhang, Jianbin Li iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.72258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Xiaopei Dong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Oncology Medicine, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Protein Kinase Inhibitors, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Endocrine therapy with CDK4/6 inhibitor has been the main treatment for HR+/HER2− breast cancer in the adjuvant setting; however, the data on the application in the neoadjuvant setting is limited. We compared neoadjuvant efficacy and safety of sequential chemotherapy‐CDK4/6 inhibitors with chemotherapy alone in HR+/HER2− breast cancer patients.

Methods

Female patients with HR+/HER2− breast cancer who received neoadjuvant therapy at the Fifth Medical Center of the PLA General Hospital from November 2019 to March 2025 were enrolled. The objective response rate (ORR), pathological complete response (pCR), and event‐free survival (EFS) between the two treatment groups were analyzed.

Results

Among the 181 enrolled patients, 142 received chemotherapy alone (NCT cohort) and 39 received CDK4/6 inhibitors plus endocrine therapy (NCT‐ET cohort) after chemotherapy as preoperative therapy. Overall pCR was similar across cohorts (3.5% in NCT cohort vs. 2.6% in NCT‐ET cohort, p = 1.000), as was ORR (72.5% vs. 69.2%, p = 0.685). The 3‐year EFS rate was numerically higher in the NCT‐ET cohort (96.7% vs. 83.6%, p = 0.111). However, among patients who failed to achieve partial response (PR) within 4 cycles of chemotherapy, switching to endocrine therapy was associated with improved ORR (61.3% vs. 30.4%, p = 0.005). Overall pCR (3.2% vs. 0.0%, p = 0.356) and 3‐year EFS rate (95.7% vs. 78.0%, p = 0.105) were numerically higher in the NCT‐ET cohort. The total incidence of grade ≥ 3 adverse effects was higher in the NCT‐ET cohort (69.2% vs. 47.8%). However, for patient received endocrine therapy after chemotherapy, grade ≥ 3 events decreased from 66.7% during chemotherapy phase to 20.5% after switching to endocrine therapy.

Conclusions

Despite no statistically significant differences in observed overall pCR and 3y‐EFS between patients treated with NCT or NCT‐ET, the sequential endocrine strategy was associated with improved ORR among patients who did not achieve PR after four cycles of chemotherapy and a lower incidence of adverse events during endocrine therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyProtein Kinase InhibitorsBreast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, HormonalChemotherapy, AdjuvantCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Receptors, EstrogenErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneProgression-Free SurvivalPathologic Complete ResponseRetrospective StudiesBreastFollow-Up StudiesResponse Evaluation Criteria in Solid TumorsHumansFemaleAdultMiddle AgedAged

Stichwörter der Autor:innen

HER2‐negativebreast cancerhormone receptor‐positiveneoadjuvant therapy

Substanzen

Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Protein Kinase InhibitorsReceptors, EstrogenErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Senior Department of Oncology Medicine, Chinese PLA General Hospital, Beijing, China.
  • Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China.
  • Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.

ORCID-Profile: Xiaopei Dong, Fan Li, Jianbin Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Dong, X., Li, F., Yuan, Y., Song, H., Wang, Y., Hao, Y., Dong, Y., Wang, T., Bian, L., Zhang, S., & Li, J. (2026). Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4 /6 Inhibitors Plus Endocrine Therapy in Patients With HR ‐Positive, HER2 ‐Negative Breast Cancer: A Retrospective Single‐Centre Cohort Analysis. Cancer Medicine. https://doi.org/10.1002/cam4.72258

Vancouver

Dong X, Li F, Yuan Y, Song H, Wang Y, Hao Y, et al. Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4 /6 Inhibitors Plus Endocrine Therapy in Patients With HR ‐Positive, HER2 ‐Negative Breast Cancer: A Retrospective Single‐Centre Cohort Analysis. Cancer Medicine. 2026. doi:10.1002/cam4.72258

BibTeX
@article{Dong2026,
  author = {Dong, Xiaopei and Li, Fan and Yuan, Yang and Song, Hua and Wang, Yingzhe and Hao, Yi and Dong, Yinping and Wang, Tao and Bian, Li and Zhang, Shaohua and Li, Jianbin},
  title = {Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4 /6 Inhibitors Plus Endocrine Therapy in Patients With HR ‐Positive, HER2 ‐Negative Breast Cancer: A Retrospective Single‐Centre Cohort Analysis},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72258}
}
Kostenlos starten →